Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2025-05-08 Regulatory Filings
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-05-08 English
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
Earnings Release Classification · 100% confidence The document is a press release titled 'argenx Reports First Quarter 2025 Financial Results and Provides Business Update'. It contains key financial highlights, a summary of business operations, and unaudited condensed consolidated interim financial statements for the three-month period ended March 31, 2025. As it is an initial announcement of quarterly financial results rather than a full interim report or a mere announcement of a report's publication, it fits the definition of an Earnings Release (ER). Q1 2025
2025-05-08 English
argenx to Present at BofA Securities 2025 Health Care Conference
Regulatory Filings Classification · 95% confidence The document is a short announcement (1544 characters) notifying the public that the company's management will be presenting at an upcoming investor conference. It does not contain the presentation slides or financial data itself, but rather serves as a notification of an event. Since it does not fit into specific categories like 'Investor Presentation' (which would contain the actual slides) or 'Earnings Release', and acts as a general regulatory/corporate announcement, it is best classified as a Regulatory Filing (RNS).
2025-05-06 English
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
Report Publication Announcement Classification · 95% confidence The document is a short announcement (1857 characters) informing stakeholders about an upcoming conference call to discuss Q1 2025 financial results. It does not contain the actual financial results or the transcript of the call. According to the 'Menu vs Meal' rule, an announcement regarding the timing of a report or a call is classified as a Report Publication Announcement (RPA).
2025-05-01 English
FORM 6-K
Regulatory Filings
2025-04-28 English
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Regulatory Filings Classification · 95% confidence The document is a press release issued by argenx announcing a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding a marketing authorization application for a drug (VYVGART). This is a standard corporate regulatory announcement regarding product development and regulatory status. Since it does not fit into specific categories like financial reports, shareholder meetings, or legal proceedings, it falls under the general regulatory announcement category.
2025-04-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.